# Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

> **NCT00922584** · PHASE2 · COMPLETED · sponsor: **Chinese Society of Lung Cancer** · enrollment: 65 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** sorafenib (Nexavar)

## Key facts

- **NCT ID:** NCT00922584
- **Lead sponsor:** Chinese Society of Lung Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-01
- **Final completion:** 2012-04
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2013-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922584, "Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00922584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*